Zobrazeno 1 - 10 of 25 pro vyhledávání: '"Paulina Selaru"'
1
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
Autor: Tony Mok, Yiyun Tang, Virote Sriuranpong, Keith D. Wilner, Paulina Selaru, Chun-Ming Tsai, Choo Khoon Ong, Elizabeth T. Masters, Jianying Zhou, Yi-Long Wu, Chin-Hee Chung, Shun Lu, Yuankai Shi, James Chung-Man Ho, You Lu
Publikováno v: Journal of Thoracic Oncology. 13:1539-1548
The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in previously untreated patients with ALK receptor tyrosine kinase gene (ALK)-positive advance
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f587fe6dbb89caa75a7e093f6ddcdb57
https://doi.org/10.1016/j.jtho.2018.06.012
Zobrazit plný text záznamu
2
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Autor: Yuankai Shi, Matthew H. Taylor, Sergey Orlov, Li Zhang, Keizo Horibe, Fadi Braiteh, Paulina Selaru, William Jeffrey Edenfield, Tae Min Kim, Jin Seok Ahn, Shang Ju Wu, Brian A. Van Tine, Kenji Tamura, Hui-Qiang Huang, Carlo Gambacorti-Passerini, Jolanda Paolini, Taito Esaki, Joseph Thaddeus Beck
Publikováno v: American Journal of Hematology
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK‐positive or ROS1‐positive advanced non‐small‐cell lung cancer (NSCLC). However, ALK rearrangements are also implicated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ff8f6d43296f0d3cf5505feea7c337
http://hdl.handle.net/10281/186038
Zobrazit plný text záznamu
3
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
Autor: E. Chmielowska, F. Gao, Richard C. Chao, C. Gridelli, E. Juhasz, Mark A. Socinski, J. A. Williams, Paul Baas, L. Tye, Harry J.M. Groen, Paulina Selaru, Charles S. Harmon, Francesco Grossi, Tiziana Usari, George R. Blumenschein, Charles A. Butts
Publikováno v: Annals of Oncology, 24(9), 2382-2389. Oxford University Press
Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC).This randomized, double-blind, multicenter,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5b8b41dc806ed11f86a06764c098dc
https://doi.org/10.1093/annonc/mdt212
Zobrazit plný text záznamu
6
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
Autor: Sindy T. Kim, Kathy S. Albain, Richard C. Chao, John T. Hamm, Gregory A. Masters, Ray D. Page, Paulina Selaru, Benjamin Besse, Radj Gervais, John D. Hainsworth, Normand Blais, Janessa Laskin, Ronald B. Natale, Allan Lipton
Publikováno v: Lung Cancer. 74:474-480
This open-label, phase II study evaluated the antitumor activity and safety of sunitinib monotherapy as maintenance treatment following first-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Follow
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2c155a347357b9ba500ad626c7987a3
https://doi.org/10.1016/j.lungcan.2011.05.004
Zobrazit plný text záznamu
7
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Autor: Timothy G. Larson, Vincent A. Miller, Lyudmila Bazhenova, Roger B. Cohen, Philip J. Stella, Shirish M. Gadgeel, Paulina Selaru, Eric B. Haura, Peter D. Eisenberg, Keith D. Wilner, Alejandro D. Ricart
Publikováno v: Clinical Cancer Research. 16:2450-2457
Purpose: To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non–small cell lung cancer patients who had experienced treatment failure after, or were refractory to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ebbfd3863a0b8740f676177e64eb98c
https://doi.org/10.1158/1078-0432.ccr-09-1920
Zobrazit plný text záznamu
9
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
Autor: Gregory A. Otterson, Cynthia Huang Bartlett, Pasi A. Jänne, L. Crinò, Sai-Hong Ignatius Ou, Dong Wan Kim, Paulina Selaru, Yiyun Tang, Darrel P. Cohen, Gregory J. Riely, Jeffrey W. Clark
BACKGROUND Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We investigated whether continuing ALK inhibition with crizotinib beyond PD (CBPD) is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6789b57041c468dc9f55ff340a7f75ef
http://hdl.handle.net/11391/1333122
Zobrazit plný text záznamu
10
Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure
Autor: Francoise Chanoine, William B. Smith, Jalal K. Ghali, Maha Ghazzi, Grady H. Hendrix, Milton L. Pressler, James E. Udelson, Christopher A. Painchaud, Ignatius Thomas, Marvin A. Konstam, Paulina Selaru
Publikováno v: Circulation. 104:2417-2423
Background Arginine vasopressin may contribute to abnormalities in hemodynamics and fluid balance in heart failure through its actions on V 1A (vascular and myocardial effects) and V 2 receptors (renal effects). Inhibiting the action of vasopressin m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee01e07a62869953d8c62d869c45622
https://doi.org/10.1161/hc4501.099313
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje